Renal Cancer - Results from #1760

Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. November 18, 2021

Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma. November 18, 2021

Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy. November 17, 2021

Kidney tumor diffusion-weighted magnetic resonance imaging derived ADC histogram parameters combined with patient characteristics and tumor volume to discriminate oncocytoma from renal cell carcinoma. November 17, 2021

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. November 16, 2021

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. November 16, 2021

The The Prognosis and Immune Microenvironment Related Factor Interleukin-23 in Clear Cell Renal Cell Carcinoma: A Radiological Investigation. November 15, 2021

[Synchronous oligometastatic renal cell carcinoma-what is the role of surgery?] November 15, 2021

Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma November 12, 2021

Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma. November 12, 2021

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. November 12, 2021

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. November 11, 2021

ROBOCOP II (ROBOtic assisted versus conventional open partial nephrectomy) randomised, controlled feasibility trial: clinical trial protocol. November 11, 2021

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial November 10, 2021

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. November 10, 2021

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? November 10, 2021

Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. November 9, 2021

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. November 9, 2021

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). November 8, 2021

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. November 8, 2021

Page 89 of 456